- Home
- ADXN vs SNSE Comparison
ADXN vs SNSE Comparison
Compare ADXN & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- SNSE
- Stock Information
- Founded
- ADXN 2002
- SNSE 2005
- Country
- ADXN Switzerland
- SNSE United States
- Employees
- ADXN N/A
- SNSE N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- ADXN Health Care
- SNSE Health Care
- Exchange
- ADXN Nasdaq
- SNSE Nasdaq
- Market Cap
- ADXN 10.1M
- SNSE 10.8M
- IPO Year
- ADXN N/A
- SNSE 2021
- Fundamental
- Price
- ADXN $8.83
- SNSE $8.17
- Analyst Decision
- ADXN Strong Buy
- SNSE Strong Buy
- Analyst Count
- ADXN 1
- SNSE 3
- Target Price
- ADXN $30.00
- SNSE $86.67
- AVG Volume (30 Days)
- ADXN 14.4K
- SNSE 12.9K
- Earning Date
- ADXN 08-11-2025
- SNSE 08-05-2025
- Dividend Yield
- ADXN N/A
- SNSE N/A
- EPS Growth
- ADXN N/A
- SNSE N/A
- EPS
- ADXN 0.10
- SNSE N/A
- Revenue
- ADXN $278,508.00
- SNSE N/A
- Revenue This Year
- ADXN $86.57
- SNSE N/A
- Revenue Next Year
- ADXN N/A
- SNSE N/A
- P/E Ratio
- ADXN $0.78
- SNSE N/A
- Revenue Growth
- ADXN N/A
- SNSE N/A
- 52 Week Low
- ADXN $6.51
- SNSE $5.00
- 52 Week High
- ADXN $13.27
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- ADXN 49.41
- SNSE 50.67
- Support Level
- ADXN $8.78
- SNSE $8.76
- Resistance Level
- ADXN $9.89
- SNSE $9.27
- Average True Range (ATR)
- ADXN 0.67
- SNSE 0.52
- MACD
- ADXN -0.03
- SNSE -0.00
- Stochastic Oscillator
- ADXN 43.01
- SNSE 42.84
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).